Flexible and scalable solutions for AAV viral vector production using a templated platform
Sponsor
Live30 webinars are thirty minute presentations designed to update you on the latest innovations, applications and data in a fast yet interactive format.
Adeno-associated virus (AAV) has become an increasingly popular viral vector for gene therapy. Currently, there are two approved AAV-based gene therapies, and the number of clinical trials is steadily increasing. As with most viral vector therapies, their production is labour intensive and expensive due to the use of adherent cell culture production processes. For process intensification, the industry has begun to utilize bioreactors. Here, we highlight our development of a suspension based AAV upstream production process to provide a more efficient and cost-effective bioprocessing solution for large scale production
- How suspension adapted cell lines for transient transfection meet AAV production needs
- The benefits of scalable solutions with simplified production processes for viral vector manufacturing
- The importance of cell line and cell culture media compliance with GMP regulations
- Robust process design, amendable to multiple transfections reagents and serotypes
SPEAKERS
You might also like
Same-section spatial multiomics: a platform for detailed analysis of the solid tumor TME
Pure and simple: understanding LNP analytics for better mRNA-based drugs
Empowering patient care: in-process and quality control solutions for cellular therapies
T cells from beginning to end: optimizing leukopak and drug product cryopreservation
